.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX09_Mogamulizumab.Mogamulizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX09_Mogamulizumab.Mogamulizumab| name: | Mogamulizumab | |
| ATC code: | L01FX09 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 3.46 | L |
| clearance: | 0.273 | L/day |
| other parameters in model implementation | ||
Mogamulizumab is a humanized monoclonal antibody targeting the CC chemokine receptor 4 (CCR4), used in the treatment of certain hematological malignancies such as relapsed or refractory adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphoma (CTCL). It is approved in several countries including Japan, EU, and the USA for these indications.
Pharmacokinetic parameters reported in adult patients with CCR4-positive T-cell lymphomas (mainly CTCL and ATL); data derived from population PK analysis.